title: [Natural history of metastasic prostate cancer treated with androgen deprivation therapy and secondary hormonal therapy efficiency].
abstract: OBJECTIVE
  to analyze metastatic prostate cancer progression in patients treated with hormonal blockade as well as second line hormonal treatments outcomes.
  
  
  METHODS
  199 metastatic patients were selected from a 455 hormonal treated patients pool. Time to biochemical progression was studied with Kaplan Meier analysis and patients were stratified according to pathological differentiation. Second line treatment lasting and efficacy were also assessed.
  
  
  RESULTS
  74 patients out of 192 metastatic patients (56.1%) progressed in terms of PSA. Median time to biochemical progression was 1.7 years (1.2-2.3, CI 95%). We did not find stadistical differences on pathological differentiation (p = 0.238). Second line treatment's efficacy, applied to 41 patients was 34.1%, without any stadistical differences among these treatments. Response treatment median time was 6.8 months without stadistical differences among different treatments (p = 0.220).
  
  
  CONCLUSIONS
  hormonal blockade efficacy in metastatic prostate cancer has a limited value in time in our experience. One third of these patients have a limited response to a second line treatment although this response is even shorter in duration.
authors: Servicio Urología Hospital Universitario de Getafe, Madrid. nuriaroga8@yahoo.es
authors: N
authors: N
authors: Rodriguez García
authors: M
authors: M
authors: Luján Galán
authors: C
authors: C
authors: Pascual Mateo
authors: A M
authors: AM
authors: García Tello
authors: G M
authors: GM
authors: Torres Zambrano
authors: A
authors: A
authors: Berenguer Sánchez
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D000726:Androgen Antagonists